Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine −

PharmaCielo Announces the Issuance of Interest Shares and Update on Insider Bridge Financing

PharmaCielo Settles Debt Interest with Equity Amidst Liquidity Concerns

By The Northwire Desk — AI Analysis May 19, 2026 · 07:31 PCLO · 0.09 Pharmacielo Ltd.
Executive Summary
  • PharmaCielo Ltd. issued 11,145,999 common shares to satisfy $891,681.85 in semi-annual interest payments on its 11% secured debentures.
  • The effective price per share for this issuance was $0.08.
  • This transaction is a related party deal involving L5 Capital Inc., Marc Lustig, William Petron, and Ian Atacan.
  • An update on the insider bridge loan facility indicates $2.5 million of a $3.0 million commitment has been utilized since February 2024 to support working capital.
  • The issuance is subject to a 4-month statutory hold period under Canadian securities laws.
  • Regulatory compliance was maintained using exemptions under MI 61-101 as the fair market value does not exceed 25% of market capitalization.
Material Impact
  • The share issuance for debt interest confirms the company's inability to service debt obligations in cash, a known risk highlighted since December 2025.
  • Since the intention to issue these shares was announced on April 17, 2026, this May 19 announcement is execution of previously disclosed plans rather than new information.
  • The dilution from issuing ~11 million shares at $0.08 is negative for existing shareholders but priced in following the April intention release.
  • The bridge loan update reveals insiders have drawn down nearly all available committed capital ($2.5M of $3M), signaling limited internal liquidity buffers remain.
  • While routine relative to prior announcements, the underlying financial distress remains material given the looming principal maturity on June 30, 2026.
PCLO · Price
Company Overview
  • PharmaCielo operates in the cannabis and pharmaceutical sector, focusing on CBD/THC product lines and GACP-certified dried flower exports.
  • Key markets include Latin America, Brazil, South Africa, Australia, and the EU.
  • The company previously divested its La Margarita property to strengthen the balance sheet and repay a Banco Agrario loan.
  • Management has stated an aim for profitability in 2026 driven by cost structure improvements and export expansion.
Read the original news release →

More from Pharmacielo Ltd.

Apr 17, 2026 · 07:31

PharmaCielo Dilutes Shareholders to Service Debt as Principal Maturity Looms

Other Mar 17, 2026 · 07:31

PharmaCielo Announces the Issuance of Interest Shares

Financings Mar 02, 2026 · 07:31

PharmaCielo Announces 2025 Q3 Results, AGM Details

Earnings Mar 02, 2026 · 07:18

SEDAR Interim Financial Statements

None Feb 17, 2026 · 19:49

Pharmacielo schedules AGM, plans debt settlement

Financings Feb 17, 2026 · 07:46

PharmaCielo Announces Annual General Meeting and Intention to Issue Interest Shares

Financings